Early results from CF STORM, a clinical trial looking at new ways to reduce treatment burden for people with CF, have now been released. Ahead of the full results from the trial in Summer 2026, Dr Gwyneth Davies based at UCL Great Ormond Street Institute of Child Health and co-Chief Investigator of the study, explains what we know so far.
Cystic Fibrosis Trust set up the Clinical Trials Accelerator Platform (CTAP) to speed up the development of new CF treatments in the UK and make it easier for people with CF to learn about taking part in clinical trials.
After two Christmases spent in hospital with cystic fibrosis, Emma's wish for 2025 is simple – a day at home with her husband, cuddles with the cats, and enough roast potatoes to go round
For many people with CF the increased socialising around the festive period can increase anxiety about developing hard to treat lung infections, that could mean long courses of antibiotics and time spent in hospital. Cystic Fibrosis Trust is funding research to develop new treatments for those infections. We spoke to CF researcher Dr Vitor Mendes about his work designing new treatments for non-tuberculous mycobacteria (NTM) infections and his festive wishes for the CF community.
For people with cystic fibrosis (pwCF), how to reduce treatment burden has been identified as the top priority research question. Daily nebulised treatments were identified by pwCF as burdensome. The CF STORM trial will recruit pwCF age 6 years and above that have been established on Kaftrio™ therapy. They will have an equal chance of being allocated to either stop or continue their daily nebulised muco-active therapies (dornase alfa, hypertonic saline or both). The trial is designed to provide confidence that stopping these nebulisers does not result in a significant decline in lung function over 12 months. The trial will...
Early results from CF STORM were released in October 2025. To find out more about these early results and what we know so far, read our blog with Dr Gwyneth Davies, the co-Chief Investigator of the study.
This Strategic Research Centre will lay important foundations for the best way to accurately test the effectiveness of new antibiotic medicines for CF lung infections. The SRC is co-funded between the Trust and the CF Foundation in the United States.
A Trust-funded Strategic Research Centre will investigate whether Magnetic Resonance Imaging (MRI) could be used to track changes in lung health over time. New MRI methods have been developed by the POLARIS group at University of Sheffield led by Professor Jim Wild, the Principal Investigator of this SRC.
